| Patent Number |
Title Of Patent |
Date Issued |
| 6838262 |
Isolated DNA molecule encoding rank ligand |
January 4, 2005 |
| Isolated ligands, DNAs encoding such ligands, and pharmaceutical compositions made therefrom, are disclosed. The isolated ligands can be used to regulate an immune response. The ligands are also useful in screening for inhibitors thereof. |
| 6824773 |
TWEAK receptor |
November 30, 2004 |
| The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogen |
| 6794173 |
Dendritic cell transmembrane serine protease |
September 21, 2004 |
| Isolated Dendritic Cell Transmembrane Serine Proteases (DCTSPs), DNAs encoding such DCTSPs, and pharmaceutical and/or diagnostic compositions made therefrom, are disclosed. The isolated DCTSPs can be used to hydrolyze peptide bonds. The DCTSPs are also useful in screening for inhibit |
| 6793919 |
Methods for treating rheumatoid arthritis using IL-17 antagonists |
September 21, 2004 |
| A method of treating a mammal afflicted with rheumatoid arthritis by administering to the mammal an antibody that binds IL-17R is disclosed. |
| 6774224 |
ULBP DNA and polypeptides |
August 10, 2004 |
| The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptid |
| 6764836 |
Interleukin-15 receptors |
July 20, 2004 |
| There are disclosed Interleukin-15 Receptor (IL-15R) proteins, DNAs and expression vectors encoding IL-15R, and processes for producing IL-15R as products of recombinant cell cultures. |
| 6762030 |
Ligand for CD7 and methods for use thereof |
July 13, 2004 |
| The invention relates to CD7 and the discovery of its cognate ligand, the K12 protein, and the identification and cloning of polynucletides that encode the murine homolog of the human K12. Also disclosed are methods of screening candidate molecules to determine potential antagonists and |
| 6759223 |
Calcium/calmodulin-dependent kinase |
July 6, 2004 |
| The invention is directed to purified and isolated novel murine and human kinase polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derive |
| 6753166 |
IL-1 eta DNA and polypeptides |
June 22, 2004 |
| The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived |
| 6740522 |
Antibodies against ligand for receptor activator of NF-kB |
May 25, 2004 |
| Provided herein are antibodies that bind human RANKL polypeptides. |
| 6727225 |
TWEAK receptor |
April 27, 2004 |
| The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogen |
| 6716587 |
Antibodies to interleukin-4 receptors and uses thereof |
April 6, 2004 |
| Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mamma |
| 6703487 |
Human pellino polypeptides |
March 9, 2004 |
| There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed. |
| 6693171 |
ACPL polypeptides |
February 17, 2004 |
| The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptid |
| 6692740 |
ACPL antibodies |
February 17, 2004 |
| The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptid |
| 6680057 |
Methods of treating autoimmune disease by administering interleukin-17 receptor |
January 20, 2004 |
| Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. |
| 6670135 |
Semaphorin polypeptides |
December 30, 2003 |
| This invention provides a method comprising assaying the binding of a DCSema polypeptide to a VESPR protein. |
| 6667039 |
CD30 ligand |
December 23, 2003 |
| There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells |
| 6664077 |
DNA encoding ACPL |
December 16, 2003 |
| The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptid |
| 6653447 |
ULBP DNA and polypeptides |
November 25, 2003 |
| The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptid |
| 6652854 |
Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or |
November 25, 2003 |
| The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF.alpha. inhibitors by administering agents |
| 6649164 |
Method for enhancing the functional capacity of dendritic cells |
November 18, 2003 |
| Isolated ligands, DNAs encoding such ligands, and pharmaceutical compositions made therefrom, are disclosed. The isolated ligands can be used to enhance the functional capacity of dendritic cells. |
| 6642358 |
Receptor that binds trail |
November 4, 2003 |
| A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors |
| 6632637 |
Vectors and methods for recombinant protein expression |
October 14, 2003 |
| There is disclosed an expression vector utilizing an internal polyadenylation signal. The internal polyadenylation signal is inserted between a DNA encoding a protein of interest and a DNA encoding a selectable marker, and allows a single promoter to generate both monocistronic messa |
| 6632424 |
Human FLTS3 ligand |
October 14, 2003 |
| Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfecte |
| 6630143 |
Antibodies against flt3 ligand |
October 7, 2003 |
| Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to anti-flt3-L antibodies and enzyme-linked immunosorbent assays comprising such |
| 6613320 |
Defective CD4+T-cells that express active CD40-L |
September 2, 2003 |
| CD4.sup.+ cells obtained from individuals with defective CD40L gene and transfected with a vector containing CD40-L are described. |
| 6605456 |
Nucleic acids encoding IKR-2, a protein kinase related to the I kappa B kinases |
August 12, 2003 |
| The invention is directed to purified and isolated kappa B kinase-related kinases 1 and 2 (IKR-1 and IKR-2) polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against t |
| 6596852 |
Antibodies that bind the cytokine designated LERK-5 |
July 22, 2003 |
| LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases. |
| 6596514 |
Expression augmenting sequence elements (EASE) for eukaryotic expression systems |
July 22, 2003 |
| There are disclosed nucleotide sequences which can improve expression of recombinant proteins two- to eight-fold in stable cell pools when present in an expression vector. |
| 6589764 |
IL-18 receptor fusion proteins |
July 8, 2003 |
| A polypeptide that functions as an IL-18 receptor is disclosed. The receptor is multimeric and includes at least one AcPL polypeptide, or fragment thereof, and at least one IL-1Rrp1 polypeptide, or fraction thereof. The receptor binds IL-18 and finds use in inhibiting biological acti |
| 6581648 |
Method and apparatus for operating a syringe and vial for injections |
June 24, 2003 |
| A device for aligning a vial and a syringe used for medical injections. The device includes a vial alignment portion and a syringe alignment portion, both aligned on an alignment axis extending between the two portions. The alignment portions can restrict motion of both the vial and the |
| 6572852 |
Method for suppressing inflammatory responses by administering TNFR |
June 3, 2003 |
| Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed. |
| 6569642 |
Receptor that binds trail |
May 27, 2003 |
| A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors |
| 6562949 |
Antibodies to viral encoded semaphorin protein receptor polypeptides |
May 13, 2003 |
| The invention is directed to VESPR polypeptides as a purified and isolated protein, the DNA encoding the VESPR polypeptide, host cells transfected with cDNAs encoding VESPR, and methods for preparing VESPR polypeptides. |
| 6562948 |
Receptor activator of NF-.kappa.B |
May 13, 2003 |
| Provided herein are isolated antibodies that specifically bind a RANK polypeptide. |
| 6555520 |
Human TSLP DNA and polypeptides |
April 29, 2003 |
| The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptid |
| 6555370 |
Bifunctional selectable fusion genes |
April 29, 2003 |
| The invention provides selectable fusion genes including a dominant positive selectable gene fused to and in reading frame with a negative selectable gene. The selectable fusion gene encodes a single bifunctional fusion protein which is capable of conferring a dominant positive selec |
| 6555354 |
TNF-.alpha. converting enzyme |
April 29, 2003 |
| A metalloprotease that converts TNF-.alpha. from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhi |
| 6548655 |
Interleukin-4 receptors |
April 15, 2003 |
| Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mamma |
| 6548644 |
Site protected protein modification |
April 15, 2003 |
| Processes for conjugating proteins with polyethylene glycol are disclosed. The disclosed processes provide modified proteins having little or no decrease in their activity and include the steps of protecting one or more sites on the protein, contacting the protected protein with polyethy |
| 6548065 |
Interleukin-15 receptors |
April 15, 2003 |
| There are disclosed Interleukin-15 Receptor (IL-15R) proteins, DNAs and expression vectors encoding IL-15R, and processes for producing IL-15R as products of recombinant cell cultures. |
| 6541610 |
Fusion proteins comprising tumor necrosis factor receptor |
April 1, 2003 |
| Fusion proteins having a tumor necrosis factor receptor (TNF-R) polypeptide and at least one additional polypeptide covalently fused thereto and selected from an interleukin-1 receptor (IL-1R) and a second TNF-R polypeptide. The receptor polypeptides are preferably fused together by a |
| 6541232 |
Polypeptides having kinase activity |
April 1, 2003 |
| Purified and isolated IL-1/TNF-.alpha.-activated kinase (ITAK), nucleic acids encoding ITAK, processes for production of recombinant forms of ITAK, pharmaceutical compositions containing ITAK, and use of ITAK in therapies and in various assays, including assays to detect antagonists |
| 6537763 |
Receptor activator of NF-.kappa.B |
March 25, 2003 |
| Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof. |
| 6528482 |
Receptor activator of NF-.kappa.B |
March 4, 2003 |
| Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof. |
| 6524817 |
DNA encoding a receptor subunit for oncostatin M |
February 25, 2003 |
| A novel polypeptide functions as the .beta. chain of an oncostatin M receptor and is thus designated OSM-R.beta.. Heterodimeric receptor proteins comprising OSM-R.beta. and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M. |
| 6521740 |
Type II Interleukin-1 receptors |
February 18, 2003 |
| Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed. |
| 6521424 |
Recombinant expression of Tek antagonists |
February 18, 2003 |
| The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions charact |
| 6521228 |
Antibodies directed against trail |
February 18, 2003 |
| A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies |
